Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.
The partnership will have a particular focus on therapies to treat sickle cell disease and HIV, with each party committing $100 million to the effort.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The company plans to use the funding to support its various microbiome-based drug development programs in oncology, food allergy and bacterial infection.
The Institute for Healthcare Improvement announced that it received a $9.6M grant from the Bill & Melinda Gates Foundation to reduce newborn mortality in Ethiopia.
While healthcare providers in the U.S. struggle with design challenges of electronic medical record systems, some other countries are still struggling to get basic paper records systems in place. A global healthcare design challenge funded by the Bill and Melinda Gates Foundation tasked designers with giving the children’s immunization record a makeover. Immunization programs are […]
The tropical disease dengue fever isn’t something we hear or worry about much in the U.S. So when virologists at the Centers for Disease Control and Prevention recently published study findings that a rare 2010 dengue outbreak in Florida came not from abroad but from a unique, local strain of the virus that’s evolved its […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
A vaccine developer focused on fighting infectious diseases like HSV-2, Pneumococcus and malaria has just gotten a $30 million vote of confidence from investors. Genocea Biosciences says its ATLAS platform mimics the human T cell immune response in the laboratory, allowing it to identify and test T cell antigens in less time and with more […]
iBio (NYSE:IBIO) is seeking to raise $10 million for its plant-based vaccine production in a public offering. The Newark, Delaware-based pharmaceutical company has priced 15,385,000 units at 65 cents per unit. Each unit includes one share of common stock and 0.75 of a warrant to purchase one share of common stock. The warrants will have an […]